who invented glp-1 The Future of Drugs and AI Medicine, With Eli Lilly CEO David Ricks History of GLP-1 Drugs: Complete

Key Points The incretins glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are gut-derived hormones that potentiate insulin secretion and contribute to glucose metabolism through a wide range of physiological actions Inhibitors of the incretin-inactivating enzyme dipeptidyl peptidase 4 (DPP-4) and DPP-4-resistant injectable GLP-1 receptor agonists have been developed for the treatment of hyperglycaemia in type 2 diabetes mellitus (T2DM) GLP-1 and other gut-derived hormones might directly and/or indirectly regulate electrolyte and fluid homeostasis by influencing feeding and drinking behaviour as well as electrolyte transport in the kidneys and gastrointestinal tract GLP-1 receptor (GLP-1R) agonists and DPP-4 inhibitors increase natriuresis in T2DM, possibly through overlapping and distinct mechanisms, and might slightly improve renal haemodynamics in the setting of diabetes-related glomerular hyperfiltration Incretin-based therapies seem to directly influence renal physiology and have indirect metabolic and haemodynamic actions that might reduce renal risk in T2DM

The Myers Cocktail is an intravenous (IV) infusion that typically contains: Unlike oral supplements, which may lose potency during digestion, IV therapy ensures 100% bioavailability by delivering nutrients directly into the bloodstream

Lee J, Hong SW, Chae SW, Kim DH, Choi JH, Bae JC, et al

Nature medicine, 29(11), 29092918

However, GLP-1RA exenatide has been shown to enhance functional connections in the hypothalamus, nucleus tractus solitarius, and thalamus

Certificate of analysis available on request